Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival

BACKGROUND: Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. IMC has been associated with improved overall survival (OS) and progression-free survival (PFS), but data are limited to a single site and predomin...

Descripción completa

Detalles Bibliográficos
Autores principales: Weingarden, Alexa R, Gubatan, John, Singh, Sundeep, Balabanis, Tatiana Clorice, Patel, Akshar, Sharma, Arpita, Habtezion, Aida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627421/
https://www.ncbi.nlm.nih.gov/pubmed/36338892
http://dx.doi.org/10.3748/wjg.v28.i39.5750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627421/
https://www.ncbi.nlm.nih.gov/pubmed/36338892
http://dx.doi.org/10.3748/wjg.v28.i39.5750

Ejemplares similares